Dinogest

Quick links to important sections

Dinogest

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dinogest

Property Description
Active ingredient Dienogest
Form Oral Tablet
Pharmacological Class Synthetic Progestogen
Common Use Hormonal modulation for tissue stabilization
Origin Semisynthetic

Dinogest: Classification and Core Identity

Dinogest is the trade name for a medicine containing the active substance Dienogest, which is classified as an orally-active, semisynthetic steroid hormone belonging to the synthetic progestogen pharmacological class. It is consistently administered in the solid oral dosage form of a tablet. Dienogest is chemically a derivative of 19-nortestosterone, defining its specialized structure as a C-19 progestogen. This specific classification is clinically recognized for providing a targeted hormonal effect, positioning Dinogest as an advanced hormonal agent utilized in gynecological practice.

Composition and Unique Actions of Dienogest

The product composition includes the active ingredient Dienogest combined with pharmaceutical excipients required for tablet formation. Dienogest’s mechanism of action functions as a powerful progesterone receptor agonist. Crucially, it is distinguished by its capacity to achieve effective suppression of the body's endogenous oestradiol (estrogen) production. This dual action, coupled with confirmed antiandrogenic activity, provides a therapeutic profile that is highly selective, minimizing off-target hormonal effects often associated with less specialized synthetic sex hormones.

General Purpose of Using This Progestogen

The general purpose of administering Dinogest is to modulate the balance of female sex hormones, creating an environment that encourages tissue stabilization and delivers symptomatic relief. By significantly diminishing the growth signals associated with estrogenic stimulation, the medicine helps to reduce the activity and proliferation of hormone-responsive cells within the pelvic area. This focused hormonal modulation is the essential physiological outcome that defines its application in addressing conditions requiring precise hormonal control.

What side effects are possible with Dinogest?

Possible Side Effects and Safety Information

The safety profile of Dinogest (Dienogest) is established through regulatory classification, distinguishing between expected, common events and rare, serious safety constraints. Adverse reactions are grouped by frequency and the physiological System-Organ-Class (SOC) affected, according to official regulatory documentation.

Frequency-Classified Adverse Reactions

The most frequently reported effects relate to changes in bleeding patterns. Officially documented adverse reactions include:

  • Common (may affect up to 1 in 10 users): Headache, depressed mood, breast discomfort, weight increased, acne, nausea, abdominal pain, flatulence, uterine/vaginal bleeding (including spotting), and asthenic conditions.
  • Uncommon (may affect up to 1 in 100 users): Migraine, dizziness, sleep disorder, anxiety, diarrhea, dry skin, alopecia, and hot flushes.

Serious Adverse Reactions and Safety Constraints

The product label includes notes on rare but clinically significant risks. These include the potential for benign hepatic tumours (and very rarely malignant tumours) and a low, but recognized, risk of Venous Thromboembolism (VTE). Continuous, heavy uterine bleeding may lead to anaemia.

Safety constraints restrict the use of Dinogest. It is contraindicated in patients with a history of or current severe hepatic disease, thromboembolic disorders, or known sex hormone-dependent malignancies. For adolescents (12 to <18 years), monitoring may be considered due to the potential for a decrease in Bone Mineral Density (BMD) during treatment. Changes in bleeding patterns are most frequent during the first months and tend to subside with longer treatment duration.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information characterizes acute overdose with Dinogest (dienogest) as having a low risk of serious acute toxicity. Symptoms are generally mild, non-life-threatening, and relate to excessive hormonal effect rather than systemic toxicity. Following an overdose, the medicine should be immediately discontinued.


Documented Manifestations and Actions

Classification Official Regulatory Statement
Documented Symptoms Nausea, vomiting, spotting (vaginal bleeding), and mild metrorrhagia (irregular or excessive bleeding).
Severe Outcomes No specific serious cardiovascular, neurological, or respiratory effects are formally documented.
Antidote No specific antidote is known for dienogest overdose.
Management Treatment is strictly symptomatic and supportive.

When Urgent Medical Help is Required

Hospital monitoring is generally not required unless the ingested dose was exceptionally high or if symptoms become severe. The official guidance is to seek immediate medical attention for any documented symptoms, such as bleeding or vomiting, that are persistent, severe, or concerning to ensure proper clinical evaluation. The profile in young children who accidentally take the medicine shows similar, non-serious symptoms.

Therapeutic Uses of Dinogest

What Dinogest Treats: Main Uses and Benefits

Dinogest is considered relevant in the long-term management of endometriosis, a chronic condition involving discomfort and the growth of tissue outside the uterus. The medication is commonly used to help with the pain associated with this disease, including persistent pelvic pain, intense menstrual pain (dysmenorrhea), and discomfort during intimacy (dyspareunia). The medication offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.

Its primary therapeutic uses include managing endometriosis, often following surgical procedures, and addressing certain hormone-related skin manifestations. Through its role in hormonal tissue management, Dinogest contributes to improved comfort during periods of heightened symptoms. This approach is relevant in clinical settings that require long-term therapeutic support, relevant for easing symptoms that may become more disruptive during flare-ups. In addition, Dinogest may assist with managing external symptoms such as acne or excessive hair growth (hirsutism). This may support general well-being during symptomatic phases.


Quick Fact: Relief for Chronic Pelvic Pain Dinogest is commonly used for conditions characterized by periods of heightened symptoms, relevant for managing symptoms that interfere with daily comfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dinogest?

Eligibility for Dinogest (Dienogest 2 mg) is strictly defined by regulatory documents, primarily restricting use to ensure patient safety regarding vascular, hepatic, and reproductive health. The medicine is indicated for use in adult women and post-menarche adolescent females.


Absolute Contraindications

Dinogest is strictly contraindicated and must not be used in the presence of the following conditions, as stated in official labeling:

  • Active or History of Thromboembolic Disorders: Including deep vein thrombosis or pulmonary embolism.
  • Cardiovascular Disease: Past or present arterial disease, such as stroke or myocardial infarction.
  • Severe Hepatic Disease: Current or history of severe liver disease, including liver tumors.
  • Sex Hormone-Dependent Malignancies: Known or suspected cancers sensitive to sex hormones.
  • Undiagnosed Vaginal Bleeding or Hypersensitivity to the ingredients.
  • Diabetes Mellitus with Vascular Involvement.

Population Restrictions

Group Official Regulatory Status
Pregnancy Must not be used; pregnancy must be excluded before treatment.
Lactation Not recommended due to progestin excretion in breast milk.
Pre-Menarche Not indicated in children prior to menarche.
Geriatric No relevant indication for use after menopause.

What should I know about interactions with other medicines?

The official interaction profile for Dienogest is defined by its pharmacokinetic clearance, which is primarily mediated by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with other substances is categorized by governmental regulators based on whether they accelerate or impede this metabolic pathway.

Interactions Affecting Plasma Concentration

Substances that act as strong or moderate CYP3A4 inhibitors are documented to reduce Dienogest clearance, potentially leading to increased systemic exposure (higher plasma concentration). This category includes certain azole antifungals, macrolide antibiotics (e.g., erythromycin), and calcium channel blockers (e.g., verapamil, diltiazem).

Conversely, strong CYP3A4 inducers accelerate the clearance of Dienogest. Regulatory documents state that this action results in reduced systemic exposure and a risk of diminished therapeutic effect. Inducers specifically listed include anti-epileptic medicines (e.g., phenytoin, carbamazepine) and rifampicin. The herbal product St. John’s Wort and Grapefruit Juice are also officially noted as modifiers that can affect Dienogest exposure.

Co-administration Restrictions and Timing

Co-administration with other steroids, such as Danazol, is generally restricted or advised against in regulatory labeling. A time-dependent condition for absorption is also noted: efficacy may be officially compromised if the Dinogest tablet is not fully absorbed due to severe vomiting or diarrhoea occurring within 3–4 hours after administration. Furthermore, interaction risks are of maximum clinical significance in populations with severe hepatic disease, a condition officially listed as a contraindication.

Mechanism of Action

Targeting the Progesterone Receptor and Inducing Tissue Atrophy

Dinogest acts as a high-affinity agonist at the Progesterone Receptor (PR), initiating a specific genetic signaling sequence in hormone-responsive tissue. This molecular action triggers decidualization followed by apoptesis, a targeted cellular process that results in the structural atrophy (regression) of the tissue mass.


Local Suppression of Estrogen and Inflammatory Pathways

This action is supported by the moderate suppression of the central hormonal axis and, crucially, by acting as an inhibitor of local enzymes like Aromatase. This dual control creates a localized environment starved of the estrogenic growth signal. Furthermore, the PR-mediated cascade dampens the production of inflammatory mediators, which modulates the release of inflammatory substances at the tissue level.


Ancillary Antiandrogenic Activity

A secondary, yet functionally distinct, mechanism involves Dinogest's activity as an antagonist at the Androgen Receptor. This mechanistic domain affects peripheral androgen signaling, a common characteristic of this class of progestogens.

Dosage and Administration Information

The administration of Dinogest follows a specific schedule to maintain a consistent daily hormonal level.

Administration Scope

Property Guideline
Route of administration Oral use (swallowed with liquid)
Dosing schedule One fixed dose tablet of 2 mg Dienogest daily.
Timing in relation to meals May be taken with or without food (Independent of meal times).
Age-group administration rules Use is not indicated in children prior to menarche (first menstrual bleeding).
Renal/Hepatic status No dosage adjustment is needed for patients with renal impairment; the medicine is contraindicated in present or past severe hepatic disease.

Official Use Protocol

Dinogest must be taken on a continuous daily schedule without any break or interruption, even during episodes of vaginal bleeding. Administration should occur at approximately the same time each day to help maintain a stable concentration of the drug. Treatment may be initiated on any day of the menstrual cycle.

If a dose is missed, the instruction is to take only one tablet as soon as the lapse is remembered, and then resume the regular schedule on the following day at the usual time. If vomiting or severe diarrhea occurs within 3 to 4 hours of intake, the tablet may be considered unabsorbed and should be replaced by taking one additional tablet.

The treatment is designed for a long-term duration, typically guided by clinical necessity over many months.

Recent Clinical Evidence

Research evidence / Overview of studies for Dinogest

This section provides an overview of what the research and studies on Dinogest have found so far. It is important to know that findings describe group patterns, not personal outcomes. Studies help show what has been observed in the populations studied, but research provides context and does not determine whether an individual will respond similarly. Evidence highlights what is known—and what is still uncertain—about this medication.


Endometriosis: Outcomes related to physical discomfort

Dinogest was studied for conditions characterized by fluctuating or episodic manifestations, which is a characteristic of endometriosis. Research examined its application in studies relevant to trials assessing short-term or episodic symptom patterns. Research monitored outcomes related to physical discomfort and explored outcomes reflecting daily functioning or activity level.

Studies report patterns observed related to changes in patient-reported outcomes describing perceived discomfort. Research describes patterns related to outcomes related to systemic or functional imbalance. This research contributes to understanding symptom patterns associated with the condition.


Evidence for Disease Progression and Recurrence

Research also explored post-surgical management strategies in studies involving this medicine. These studies focused on outcomes describing episodic or acute changes, specifically the rate of recurrence of lesions or symptoms over time. Studies monitored outcomes related to physical discomfort in premenopausal women who had undergone conservative surgery. Findings from these analyses contribute to the broader evidence landscape regarding long-term management strategies.


Outcomes related to Systemic and Functional Imbalance

Research focused on outcomes related to systemic or functional imbalance, such as volume and duration of bleeding, which is a key part of outcomes linked to inflammatory or irritative states. This research was evaluated in observational settings evaluating daily-life functioning for conditions involving periods of heightened symptoms. Studies report measurements related to outcomes related to systemic or functional imbalance.


Research Gaps and Limitations

Long-term effects are not fully established. Follow-up durations were limited in many trials, meaning there is limited information for long-term outcomes. Evidence quality varies across studies, and certainty remains low regarding sustained changes beyond the measured study period. Comparative evidence is lacking when looking at Dinogest alongside all other possible treatments. Data for certain groups remain insufficient; for instance, evidence is limited in populations outside of the primary reproductive age group. Results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Dinogest (FAQ)

Q: What is the main condition Dinogest is approved to treat?

According to regulatory documentation, Dinogest (Dienogest) is officially indicated for the management and treatment of endometriosis-associated pelvic pain.

Q: Is Dinogest a type of hormone replacement therapy?

Dinogest is classified as a single-agent, synthetic progestogen medicine. It is not classified as Hormone Replacement Therapy (HRT) for its officially approved use.

Q: How quickly can I expect Dinogest to start working for pain relief?

Studies examining the medicine’s effect on pain relief typically report observing a significant decrease in pelvic pain during continued treatment over time. This effect is often monitored in clinical trials over periods of 12 and 24 weeks.

Q: Can Dinogest be used for heavy or painful periods if I do not have the treated condition?

The official regulatory indication for Dinogest is strictly for the treatment of endometriosis-associated pelvic pain. Official product documents do not provide information on its use for other conditions.

Q: Does Dinogest affect fertility or the ability to get pregnant after stopping it?

Studies have examined the pattern of return to fertility after patients have stopped using Dinogest. It is officially stated that the medicine is not approved as a contraceptive and non-hormonal contraception is generally required to be utilized if needed during treatment.

Q: Is Dinogest the same thing as the birth control pill?

Official product documentation states that Dinogest is not approved as a primary contraceptive on its own. If contraception is required while using the medicine, it is generally required to be utilized alongside non-hormonal methods to prevent pregnancy.

Q: What are the most common reasons people are prescribed Dinogest?

Dinogest is officially approved and prescribed for the management of symptoms associated with endometriosis-associated pelvic pain.

Q: Is Dinogest considered a form of contraception?

No, Dinogest is not approved as a primary contraceptive. Official product documents state that if contraception is required during its use, non-hormonal methods are generally required to be utilized.

Q: Can men take Dinogest for any reason?

Dinogest is officially indicated for use only in adult women and post-menarche adolescent females. Official regulatory documentation does not state any relevant indication for its use in men.

Q: Are there certain foods or drinks I should avoid while taking Dinogest?

Official regulatory documents state that Dinogest can be taken with or without food. However, grapefruit juice is specifically noted as a substance that may affect the body's exposure to the medicine, and a need for caution regarding its consumption is noted in official documents.

Q: Can Dinogest interact with common over-the-counter pain relievers?

Dinogest is broken down in the body mainly by an enzyme system called CYP3A4. Official documents list medicines like certain antibiotics and antifungals that can interact with this system, which may change the concentration of Dinogest in your blood.

Q: Are there any known issues with taking Dinogest before surgery?

Official documents list an existing or active venous thromboembolic disorder (VTE, or blood clots) as a strict contraindication for this medicine. Due to the general risk of blood clots associated with surgery, official warnings signal that temporary discontinuation is generally discussed in the context of major planned procedures.

Q: Are there any research studies looking into new uses for Dinogest?

Official regulatory documents define the single approved indication for this medicine. Research overviews usually focus on the safety and efficacy outcomes related to that approved condition. Any discussion of unapproved uses is outside the scope of the medicine's official labeling.

Q: What is the general expectation for how Dinogest impacts symptoms?

The general purpose of Dinogest is described as modulating hormones to encourage tissue stabilization and deliver symptomatic relief. Clinical studies have shown that the treatment is associated with a reduction in symptoms like pelvic pain related to the treated condition.

Q: What does 'contraindication' mean in the context of Dinogest?

In the context of Dinogest, a contraindication is an official condition or circumstance that makes the use of the medicine strongly inadvisable. Regulatory documents use this term to signal situations, such as specific diseases or patient history, where taking the medicine could potentially cause serious harm.

Q: What is the expected long-term safety profile of Dinogest?

Official research overviews note that the duration of follow-up was limited in some trials, meaning long-term effects are not fully established. Known risks noted in regulatory documents include the potential for rare benign hepatic tumours and a decrease in Bone Mineral Density (BMD) when used by adolescents.

Q: Will Dinogest stop my menstrual cycle completely?

Official documents note that uterine/vaginal bleeding (including spotting) is a common effect, particularly during the first months of use. While Dinogest often causes changes in the pattern and flow of the menstrual cycle, there is no official guarantee that the cycle will stop completely for all users.

Q: Can Dinogest affect my blood pressure or cholesterol levels?

The official safety information lists a contraindication related to hypertension with vascular disease. The active ingredient, Dienogest, is generally noted for having a lack of significant effect on the body's metabolic and lipid systems, which include cholesterol.

Q: Can I drink alcohol while taking Dinogest?

Official product documentation and drug interaction warnings do not typically include specific statements regarding moderate alcohol consumption. However, the regulatory documentation notes the existence of risk factors for vascular disease, which may be compounded by certain lifestyle choices.

Q: What happens when I stop taking Dinogest?

Studies have observed that after stopping the treatment, bleeding patterns typically return to normal. The reduction in symptoms like pelvic pain may persist for a certain duration after discontinuation in some patients.

Q: Can Dinogest be taken if I also have fibroids?

Official warnings in the regulatory documents advise that Dinogest may aggravate menstrual blood loss in patients who also have uterine fibroids (leiomyomas) or adenomyosis.

Q: Does Dinogest need a prescription?

Yes, according to regulatory authorities, Dinogest is classified as a prescription-only medicine (POM). It requires authorization from a licensed healthcare professional.

Q: Can Dinogest interact with blood thinning medications?

Official documentation lists active venous thromboembolic disorder (blood clots) as a strict contraindication for Dinogest. The listing of this contraindication highlights the importance of discussing all medications that affect the body's coagulation system.

Q: Why do official documents advise caution with Dinogest in smokers?

Official documents note that caution is exercised because contraindications for the medicine relate to thromboembolic disorders and cardiovascular disease. These specific health risks are significantly increased in patients who smoke.

Q: Is Dinogest used to manage symptoms or to treat the root cause of the condition?

The medicine is described as delivering symptomatic relief from pain. Additionally, its mechanism of action involves inducing atrophy—a targeted cellular process resulting in the regression of the affected tissue mass.

Q: Do studies suggest Dinogest is more effective than placebo?

Studies comparing Dinogest to a placebo found that the medicine was significantly more effective than placebo in reducing the level of associated pelvic pain in patients with the treated condition.

How should Dinogest be stored and disposed of?

How to Store and Dispose of Dinogest?

Dinogest (dienogest) tablets must be stored according to official regulatory requirements to maintain product stability and ensure safety.

Storage and Stability

  • Temperature: Store at Controlled Room Temperature, generally up to 30 C (86 F).
  • Protection: The medicine must be kept in its original outer carton to protect the tablets from light.
  • Child Safety: Keep this medicine out of the sight and reach of children.

Disposal Requirements

Expired or unused Dinogest should not be discarded into the environment.

  • Environmental Restriction: Do not dispose of the medicine via wastewater or household waste.
  • Procedure: Any unused product must be disposed of in accordance with local requirements. Patients should consult a pharmacist for guidance on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dinogest found in:

A-Z Index: